Free Trial
→ The system holding the dollar together is gone… (From Golden Portfolio) (Ad)tc pixel
NASDAQ:GNPX

Genprex 8/14/2025 Earnings Report

Genprex logo
$0.83 -0.02 (-2.16%)
As of 12:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Genprex EPS Results

Actual EPS
-$8.50
Consensus EPS
-$35.50
Beat/Miss
Beat by +$27.00
One Year Ago EPS
N/A

Genprex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genprex Announcement Details

Quarter
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Genprex Earnings Headlines

Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel
April 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-expands-reqorsa-cancer-therapy-patent-protection-in-israel?utm_source=marketbeat.com&utm_medium=referral
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
April 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-receives-patent-grant-from-the-israel-patent-office-for-the-combination-of-reqorsa-gene-therapy-and-pd-1-antibodies-to-treat-cancer-302758043.html
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
May 12 at 1:00 AM  |  Porter & Company (Ad)
Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy
April 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-highlights-promising-preclinical-data-for-diabetes-gene-therapy?utm_source=marketbeat.com&utm_medium=referral
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
April 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-diabetes-gene-therapy-for-type-2-diabetes-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting-302755179.html
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
April 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/positive-clinical-data-on-biomarkers-in-patients-receiving-reqorsa-gene-therapy-to-be-released-at-the-2026-asco-annual-meeting-302749710.html
See More Genprex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email.

About Genprex

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes. This preclinical program seeks to deliver genes that support insulin production and glucose regulation, laying the groundwork for future clinical development in metabolic diseases. By leveraging its gene delivery platform, the company aims to expand its pipeline into other oncology and metabolic indications over time.

Headquartered in Austin, Texas, Genprex operates under a management team with deep experience in gene therapy research and biopharmaceutical development. The company collaborates with leading academic and clinical research centers to conduct its studies, ensuring rigorous trial design and patient enrollment. Through these partnerships, Genprex seeks to translate cutting-edge genetic science into transformative therapies for patients with high-unmet medical needs.

View Genprex Profile
Earnings Tools